Revolution Medicines announced that the U.S. FDA has accepted its New Drug Application for daraxonrasib, an oral targeted therapy for previously treated metastatic pancreatic ductal adenocarcinoma (PDAC). This acceptance follows positive Phase 3 trial results showing improved survival and quality of life compared to chemotherapy. Daraxonrasib targets RAS mutations, a key driver of pancreatic cancer, and has received special FDA designations to expedite review. The company is also pursuing regulatory review in Europe, aiming to bring this new treatment option to patients with limited alternatives.
Tapestry's stock is rated Buy following a sharp sell-off after its earnings report, driven by strong performance from Coach, which is fueling high-margin growth and international expansion. Coach's pricing power, success in attracting Gen Z customers...
XRP briefly fell below the key $1 level on August 16 before recovering to around $1.06 during a volatile session. Veteran trader Peter Brandt criticized XRP, stating he would convert a hypothetical 500,000 XRP holding into Bitcoin immediately, reflec...
Solana's token (SOL) is now accessible for trading on the XRP Ledger's native decentralized exchange through a wrapped SOL asset issued by Axelar. This development enhances interoperability between the Solana and XRP Ledger ecosystems, allowing users...
Dogecoin is showing technical signs of a potential upward move, with a key resistance level at $0.0813 where 30 billion DOGE were previously transacted. If Dogecoin sustains a close above this level, it could target the next resistance at $0.177. The...
Micron Technology's stock has recently dropped 11% but is now showing signs of recovery, crossing key moving averages that suggest a tactical short-term buying opportunity. The DRAM and NAND memory markets remain tight, driven by strong demand from A...
